Preliminary results of the 4AC-4THP neoadjuvant treatment for HER2 positive breast cancer

Tóm tắt

Objective: To assess the preliminary efficacy of the 4AC-4THP neoadjuvant treatment regimen in patients diagnosed with HER2-positive breast cancer. Patients and Methods: This retrospective descriptive study included 38 eligible patients with confirmed HER2-positive breast cancer treated with the 4AC-4THP neoadjuvant regimen from January 2016 to February 2025 at Hanoi Medical University Hospital, Vietnam National Cancer Hospital, and Hanoi Oncology Hospital. Results: Among the 38 patients enrolled in the study, the median age was 43.29 years old (range 28 - 62). The cohort included 21 patients (55.3%) in stage II and 17 patients (44.7%) in stage III. The average tumor size measured 42.05mm, with a hormone receptor positivity rate of 34.2%. The total pathological complete response (tpCR) was achieved in 78.9% (30 out of 38 patients). No statistically significant correlation- was observed between tpCR rates and factors such as age, clinical stage, tumor size, histological grade, Ki-67 index, hormone receptor status, or treatment regimen. There was no evidence of disease progression during the neoadjuvant treatment. The most frequent grade 3 and 4 adverse events were neutropenia and nausea/vomiting, reported at rates of 13.1% and 10.5%, respectively. No patient experienced treatment discontinuation due to cardiovascular events or other serious adverse effects. Conclusion: The 4AC-4THP neoadjuvant regimen demonstrates high efficacy and an acceptable safety profile in the treatment of HER2-positive breast cancer in this cohort.